Results 151 to 160 of about 3,704,275 (297)

Histone deacetylase inhibitors as venetoclax‐sensitising partners in acute myeloid leukaemia: Mechanisms, pharmacology and translational perspectives

British Journal of Pharmacology, EarlyView.
Abstract Venetoclax combined with hypomethylating agents has improved treatment for older or unfit patients with acute myeloid leukaemia (AML), but resistance and relapse remain common. This review analyses the rationale for combining venetoclax with inhibitors of histone deacetylase (HDAC).
Jaebok Lee, Marc Diederich
wiley   +1 more source

Retinoic Acid Receptor Is a Novel Therapeutic Target for Postoperative Cognitive Dysfunction. [PDF]

Pharmaceutics, 2023
Bao Y, Rong W, Zhu A, Chen Y, Chen H, Hong Y, Le J, Wang Q, Naman CB, Xu Z, Liu L, Cui W, Wu X.   +12 more
europepmc   +1 more source

New Treatment Strategy and Future Research Direction for BRAF‐Mutated Cancer

Cancer Science, EarlyView.
Treatment with BRAF inhibitor plus MEK inhibitor is currently used in BRAF‐mutated various malignancies except colorectal cancer, and treatments with BRAF and/or MEK inhibitors and anti‐EGFR antibody are used in BRAF‐mutated colorectal cancer. Despite recent advances in BRAF‐targeted therapies, their efficacy is still limited.
Masanobu Takahashi, Sakura Hiraide Taniguchi, Yuya Yoshida   +2 more
wiley   +1 more source

Clinical and functional heterogeneity associated with the disruption of retinoic acid receptor beta. [PDF]

Genet Med, 2023
Caron V, Chassaing N, Ragge N, Boschann F, Ngu AM, Meloche E, Chorfi S, Lakhani SA, Ji W, Steiner L, Marcadier J, Jansen PR, van de Pol LA, van Hagen JM, Russi AS, Le Guyader G, Nordenskjöld M, Nordgren A, Anderlid BM, Plaisancié J, Stoltenburg C, Horn D, Drenckhahn A, Hamdan FF, Lefebvre M, Attie-Bitach T, Forey P, Smirnov V, Ernould F, Jacquemont ML, Grotto S, Alcantud A, Coret A, Ferrer-Avargues R, Srivastava S, Vincent-Delorme C, Romoser S, Safina N, Saade D, Lupski JR, Calame DG, Geneviève D, Chatron N, Schluth-Bolard C, Myers KA, Dobyns WB, Calvas P, DDD Study, Salmon C, Holt R, Elmslie F, Allaire M, Prigozhin DM, Tremblay A, Michaud JL.   +54 more
europepmc   +1 more source

Long Non‐Coding RNA, Like NEAT1 and MALAT1, in Asthma: Mechanisms and Therapeutic Potential

Clinical &Experimental Allergy, EarlyView.
Long non‐coding RNA, like NEAT1 and MALAT1, is emerging as a regulator of asthma‐related inflammation, airway remodelling, viral responses and cell death pathways, and are promising targets for future therapeutics. ABSTRACT Asthma affects millions worldwide. Long non‐coding RNA (lncRNA) are emerging as important factors in the pathophysiology of asthma
Ashlyn Poole, Ingrid Laing, Ryan Mead‐Hunter, Peter Le Souef, Guicheng Zhang   +4 more
wiley   +1 more source

Retinoic Acid Receptor γ Is a Ligand-Activated Gatekeeper to Stem Cell Developmental Progression. [PDF]

Int J Mol Sci
Johnson WEB, McQueen C, Brown G.
europepmc   +1 more source

Retinoic acid receptor regulation of decision-making for cell differentiation. [PDF]

Front Cell Dev Biol, 2023
Brown G.
europepmc   +1 more source

Lactate‐Primed NETosis Modulates Hepatic Regeneration During Acute Liver Failure via the TLR9/KLF15/AJUBA Axis

Cell Proliferation, EarlyView.
This study elucidates a novel Kupffer cell‐neutrophil‐hepatocyte axis that drives metabolic‐immune crosstalk during acute liver failure. Specifically, lactate‐primed NETs release links metabolic reprogramming to NETosis‐induced regenerative failure in hepatocytes via the TLR9/KLF15/AJUBA axis.
Jin Guo, Xiaoya Zhang, Danmei Zhang, Chunxia Shi, Luwen Wang, Zuojiong Gong   +5 more
wiley   +1 more source

Transmembrane mucin 21 drives lung adenocarcinoma growth by suppressing retinoic acid receptor β signaling. [PDF]

J Thorac Dis
Lv W, Huang X, Cheng X, Wang Y, Wu L, Zhu Y.   +5 more
europepmc   +1 more source

Insufficient support for retinoic acid receptor control of synaptic plasticity through a non-genomic mechanism. [PDF]

Front Neuroendocrinol, 2023
Duester G.
europepmc   +1 more source